Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa
Abstract Background Although direct-acting antivirals (DAA) have become standard care for patients with chronic hepatitis C worldwide, there is no evidence for their value for money in sub-Saharan Africa. We assessed the cost-effectiveness of four sofosbuvir-based regimens recommended by the World H...
Saved in:
Main Authors: | Sylvie Boyer (Author), Maël Baudoin (Author), Marie Libérée Nishimwe (Author), Melina Santos (Author), Maud Lemoine (Author), Gwenaëlle Maradan (Author), Babacar Sylla (Author), Charles Kouanfack (Author), Patrizia Carrieri (Author), Abbas Mourad (Author), Nicolas Rouveau (Author), Raoul Moh (Author), Moussa Seydi (Author), Alain Attia (Author), Maame Esi Woode (Author), Karine Lacombe (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Free access to antiretroviral treatment and protection against the risk of catastrophic health expenditure in people living with HIV: evidence from Cameroon
by: Marwân-, et al.
Published: (2021) -
Sofosbuvir: A Potential Treatment for Ebola
by: Sandra E. Reznik, et al.
Published: (2018) -
Potential Use of Sofosbuvir in the Prophylaxis for Rabies
by: Sandra E. Reznik, et al.
Published: (2020) -
Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis
by: Hussien Ahmed, et al.
Published: (2018) -
Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020)